ROSSARI452.00

Rossari Biotech Limited

· Chemicals
₹ CrorePeersNOCILHSCLNAVINFLUORDDEVPLSTIKCHEMPLASTSTATACHEMAARTIINDJGCHEMMcap ₹2,503 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation60.467.179.1
+ Finance Costs19.417.827.2
+ Interest Income-2.2-0.9-1.4
+ Fair Value (Gains) / Losses0.10.00.0
+ Share-based Payments0.70.13.3
+ Unrealised FX (Gain) / Loss-0.50.3-2.3
+ Other Non-cash Items3.60.20.3
+ Other — Cash Effects are Investing / Financing-4.4-1.8-20.5
Changes in Working Capital
+ Inventories-93.8-72.8-49.5
+ Trade Receivables — Current-112.6-85.4-134.9
+ Trade Payables — Current49.385.130.5
+ Provisions — Current0.02.71.2
Cash from Operating Activities
Profit Before Tax (per I/S)177.4184.2200.6247.8
+ Total Adjustments (incl. Working Capital)-80.312.4-66.8
Cash from Operations (pre-tax)97.1196.6133.8
+ Income Taxes Paid53.959.268.8
Cash from Operating Activities43.3137.465.1
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)131.3158.5264.7
+ Disp of Fixed Assets5.50.024.2
+ Purchase of Investments (Equity / Debt)9.017.80.0
+ Sale of Investments (Equity / Debt)0.00.023.1
+ Acq of Subsidiaries / Businesses (net)17.70.30.0
+ Dividends Received — Investing0.10.01.2
+ Interest Received — Investing2.60.71.5
+ Other Inflows / (Outflows) — Investing46.6-7.8-4.8
Cash from Investing Activities-103.2-183.7-219.5
Cash from Financing Activities
+ Proceeds from Issue of Shares0.00.00.8
+ Proceeds from Other Equity Instruments3.85.10.0
+ Proceeds from Borrowings43.5120.7239.6
+ Repayment of Borrowings11.638.619.6
+ Payment of Lease Liabilities0.83.06.6
+ Interest Paid16.016.525.2
+ Dividends Paid2.82.82.8
Cash from Financing Activities16.264.9186.3
Net Changes in Cash (pre-FX)-43.818.631.9
+ Effect of FX Rate Changes on Cash-0.30.4-0.8
Net Changes in Cash-44.019.031.1
Closing Cash25.2
Reference Items
EBITDA249.8265.1285.9366.5
EBITDA Margin %13.6412.7411.9311.85
Free Cash Flow (CFO − Capex)-88.0-21.1-199.6-199.6
Free Cash Flow to Equity44.6-4.8
Free Cash Flow per Basic Share-15.89-3.80-36.04-36.04
Cash Flow to Net Income0.331.010.44
Cash Paid for Taxes53.959.268.8
Cash Paid for Interest16.016.525.2
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.